Welcome to LookChem.com Sign In|Join Free

CAS

  • or

4841-84-3

Post Buying Request

4841-84-3 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

4841-84-3 Usage

Uses

Dimethyl cis-1,2,3,6-tetrahydrophthalate may be used in chemical synthesis.

General Description

Epoxidation of dimethyl cis-1,2,3,6-tetrahydrophthalate has been reported. Desymmetrization of dimethyl cis-1,2,3,6-tetrahydrophthalate to (1S,2R)-1-methyl-cis-1,2,3,6-tetra-hydrophthalate has been reported.

Check Digit Verification of cas no

The CAS Registry Mumber 4841-84-3 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 4,8,4 and 1 respectively; the second part has 2 digits, 8 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 4841-84:
(6*4)+(5*8)+(4*4)+(3*1)+(2*8)+(1*4)=103
103 % 10 = 3
So 4841-84-3 is a valid CAS Registry Number.
InChI:InChI=1/C10H14O4/c1-13-9(11)7-5-3-4-6-8(7)10(12)14-2/h3-4,7-8H,5-6H2,1-2H3/t7-,8+

4841-84-3 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Alfa Aesar

  • (H25952)  Dimethyl cis-4-cyclohexene-1,2-dicarboxylate, 99%   

  • 4841-84-3

  • 1g

  • 218.0CNY

  • Detail
  • Alfa Aesar

  • (H25952)  Dimethyl cis-4-cyclohexene-1,2-dicarboxylate, 99%   

  • 4841-84-3

  • 10g

  • 1058.0CNY

  • Detail

4841-84-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 11, 2017

Revision Date: Aug 11, 2017

1.Identification

1.1 GHS Product identifier

Product name DiMethyl cis-4-Cyclohexene-1,2-dicarboxylate

1.2 Other means of identification

Product number -
Other names Dimethyl cis-4-Cyclohexene-1,2-dicarboxylate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:4841-84-3 SDS

4841-84-3Relevant articles and documents

A diastereoselective P450-catalyzed epoxidation reaction: Anti versus syn reactivity This Letter is dedicated to the memory of Harry Wasserman

Ilie, Adriana,Lonsdale, Richard,Agudo, Rubén,Reetz, Manfred T.

, p. 3435 - 3437 (2015)

The achiral cyclohexene derivative dimethyl cis-1,2,3,6-tetrahydrophthalate has been subjected to oxidation catalyzed by cytochrome P450 monooxygenase P450-BM3, leading to diastereoselective epoxidation rather than oxidative hydroxylation. This reaction occurs with 94% diastereoselectivity in favor of the anti-epoxide, in contrast to m-CPBA which delivers unselectively a 70:30 mixture of anti/syn diastereomers. The experimental results are nicely explained on a molecular level by docking experiments and molecular dynamics computations.

Novel 1,2,3-triazole compounds: Synthesis, In vitro xanthine oxidase inhibitory activity, and molecular docking studies

Tan, Ayse

, (2020)

In this study, novel 1,2,3-triazole compounds containing carbasugar frameworks (5 and 6) were synthesized by the copper-catalyzed azide-alkyne cycloaddition reactions and their in vitro inhibition effects on the enzyme xanthine oxidase were investigated. All of the synthesized compounds were characterized by spectroscopic methods. According to the enzyme inhibition results, compounds 5 (IC50 = 0.586 ± 0.017 μM) and 6 (IC50 = 0.751 ± 0.021 μM) showed stronger inhibition effects than allopurinol (IC50 = 1.143 ± 0.019 μM), which is a standard drug used for inhibition of xanthine oxidase. The binding modes of the 1,2,3-triazole compounds (5 and 6) with the active site of xanthine oxidase were explained based on molecular docking studies. The molecular docking studies showed that the aromatic structure, π-π interactions and hydrophobic interactions play a major role in xanthine oxidase inhibition for compounds 5 and 6.

PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS

-

Page/Page column 299-300; 360-362, (2020/10/18)

This disclosure provides pharmaceutical compounds to treat medical disorders, such as complement-mediated disorders, including complement Cl -mediated disorders.

Trans-hydrogenation: Application to a concise and scalable synthesis of brefeldin a

Fuchs, Michael,Fürstner, Alois

supporting information, p. 3978 - 3982 (2015/03/30)

The important biochemical probe molecule brefeldin A (1) has served as an inspirational target in the past, but none of the many routes has actually delivered more than just a few milligrams of product, where documented. The approach described herein is clearly more efficient; it hinges upon the first implementation of ruthenium-catalyzed trans-hydrogenation in natural products total synthesis. Because this unorthodox reaction is selective for the triple bond and does not touch the transannular alkene or the lactone site of the cycloalkyne, it outperforms the classical Birch-type reduction that could not be applied at such a late stage. Other key steps en route to 1 comprise an iron-catalyzed reductive formation of a non-terminal alkyne, an asymmetric propiolate carbonyl addition mediated by a bulky amino alcohol, and a macrocyclization by ring-closing alkyne metathesis catalyzed by a molybdenum alkylidyne.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 4841-84-3